BriaCell Therapeutics (TSE:BCT) Shares Up 2.8% – Still a Buy?

BriaCell Therapeutics Corp. (TSE:BCT)’s stock price shot up 2.8% during mid-day trading on Monday . The company traded as high as C$5.92 and last traded at C$5.86. 10,031 shares traded hands during trading, a decline of 68% from the average session volume of 30,866 shares. The stock had previously closed at C$5.70.

BriaCell Therapeutics Stock Up 2.8%

The stock has a market capitalization of C$42.49 million, a P/E ratio of -0.41 and a beta of 2.37. The firm’s 50-day simple moving average is C$5.94 and its 200 day simple moving average is C$11.09.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.